Meningococcal infection is the leading cause of serious invasive disease in the world. This pathogen is responsible for most of the sepsis and meningitis that occur and continues to be a serious public health problem, causing great social alarm.
It is a devastating disease that, in a few hours, causes a previously healthy patient to pass an extremely serious medical situation. Although its incidence is not very high, it causes death in 10% of cases and leaves severe sequelae in 20% of them, affecting any age of life.
Meningococcal B vaccine is now available for out-of-hospital use. . It is injected intramuscularly and the number of doses varies between 2 and 4, depending on the age of the patient in the first dose.
In Spain it is not funded by the National Health System, although the Spanish Association of Pediatrics recommends it since last year. . .
The vaccine has no contraindications , except in case of hypersensitivity to any of its components. In clinical trials in infants vaccinated at 2, 4 and 6 months of age, fever was reported in many of the children when Bexsero was coadministered with standard vaccines; on the other hand, in the subjects who were injected with only the bexser, fever appeared in a smaller number.. As the temperature increased, it usually followed a predictable pattern and disappeared, in most cases, the day after the injection. . .